Infections in children with down syndrome and acute myeloid leukemia: a report from the Canadian infections in AML research group

Table 2 Course characteristics and infection outcomes according to acute myeloid leukemia protocol type (N = 157)

	DS-specific AML protocol (N = 59)	Non-DS AML protocol (N = 98)
Course characteristics
Number with neutropenia (ANC <0.5 x10⁹) at start of course (%)	5 (8.4)	12 (12.5)^a
Median days with neutropenia (IQR)	11.0 (3.0, 21.0)	16.0 (7.0, 25.0)
Median days receiving steroids (IQR)	0.0 (0.0, 2.0)	2.0 (0.0, 5.0)
Supportive care
Co-trimoxazole prophylaxis (%)	41 (69.5)	66 (67.4)
Fluconazole prophylaxis (%)	28 (47.5)	39 (39.8)
Infection outcomes ^b
Microbiologically documented sterile site infection (%)	7 (11.9)	14 (14.3)
Bacteremia (%)	6 (10.2)	10 (10.2)
Sterile site Gram-positive bacteria (%)	5 (8.5)	9 (9.2)
Sterile site Gram-negative bacteria (%)	2 (3.4)	6 (6.1)
Sterile site fungus (%)	0 (0.0)	1 (1.0)
Clinically documented infection (%)	7 (11.9)	29 (29.6)
Sepsis (%)	1 (1.7)	3 (3.1)
Infectious death (%)	0 (0.0)	0 (0.0)

Abbreviations: ANC absolute neutrophil count, IQR interquartile range, AML acute myeloid leukemia, DS Down syndrome.
^aANC not available at start of 2 courses.
^bInfection outcomes represent at least one event per course.

ISSN: 1750-9378